Infectious Diseases (except HIV/AIDS)

  1. Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial

    1. Youyi Fong
    2. Adrian B. McDermott
    3. David Benkeser
    4. Sanne Roels
    5. Daniel J. Stieh
    6. An Vandebosch
    7. Mathieu Le Gars
    8. Griet A. Van Roey
    9. Christopher R. Houchens
    10. Karen Martins
    11. Lakshmi Jayashankar
    12. Flora Castellino
    13. Obrimpong Amoa-Awua
    14. Manjula Basappa
    15. Britta Flach
    16. Bob C. Lin
    17. Christopher Moore
    18. Mursal Naisan
    19. Muhammed Naqvi
    20. Sandeep Narpala
    21. Sarah O’Connell
    22. Allen Mueller
    23. Leo Serebryannyy
    24. Mike Castro
    25. Jennifer Wang
    26. Christos J. Petropoulos
    27. Alex Luedtke
    28. Ollivier Hyrien
    29. Yiwen Lu
    30. Chenchen Yu
    31. Bhavesh Borate
    32. Lars W. P. van der Laan
    33. Nima S. Hejazi
    34. Avi Kenny
    35. Marco Carone
    36. Daniel N. Wolfe
    37. Jerald Sadoff
    38. Glenda E. Gray
    39. Beatriz Grinsztejn
    40. Paul A. Goepfert
    41. Susan J. Little
    42. Leonardo Paiva de Sousa
    43. Rebone Maboa
    44. April K. Randhawa
    45. Michele P. Andrasik
    46. Jenny Hendriks
    47. Carla Truyers
    48. Frank Struyf
    49. Hanneke Schuitemaker
    50. Macaya Douoguih
    51. James G. Kublin
    52. Lawrence Corey
    53. Kathleen M. Neuzil
    54. Lindsay N. Carpp
    55. Dean Follmann
    56. Peter B. Gilbert
    57. Richard A. Koup
    58. Ruben O. Donis
    59. the Janssen Team
    60. the Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team
    61. the United States Government (USG)/CoVPN Biostatistics Team

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  2. Genomic epidemiology of Delta SARS-CoV-2 during transition from elimination to suppression in Aotearoa New Zealand

    1. Lauren Jelley
    2. Jordan Douglas
    3. Xiaoyun Ren
    4. David Winter
    5. Andrea McNeill
    6. Sue Huang
    7. Nigel French
    8. David Welch
    9. James Hadfield
    10. Joep de Ligt
    11. Jemma L. Geoghegan

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study

    1. Snežana Medić
    2. Cleo Anastassopoulou
    3. Zagorka Lozanov-Crvenković
    4. Vladimir Vuković
    5. Nataša Dragnić
    6. Vladimir Petrović
    7. Mioljub Ristić
    8. Tatjana Pustahija
    9. Zoran Gojković
    10. Athanasios Tsakris
    11. John P.A. Ioannidis

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. Self-reported mask use among persons with or without SARS CoV-2 vaccination —United States, December 2020–August 2021

    1. Lydia E. Calamari
    2. Ashley H. Tjaden
    3. Sharon L. Edelstein
    4. William S. Weintraub
    5. Roberto Santos
    6. Michael Gibbs
    7. Johnathan Ward
    8. Michele Santacatterina
    9. Alain G. Bertoni
    10. Lori M. Ward
    11. Sharon Saydah
    12. Ian D. Plumb
    13. Michael S. Runyon

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Time series cross-correlation between home range and number of infected people during the COVID-19 pandemic in a suburban city

    1. Haruka Kato
    2. Atsushi Takizawa

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals

    1. Johannes Leiner
    2. Vincent Pellissier
    3. Sven Hohenstein
    4. Sebastian König
    5. Ekkehard Schuler
    6. Robert Möller
    7. Irit Nachtigall
    8. Marzia Bonsignore
    9. Gerhard Hindricks
    10. Ralf Kuhlen
    11. Andreas Bollmann

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients

    1. Hye Kyung Lee
    2. Ludwig Knabl
    3. Mary Walter
    4. Priscilla A. Furth
    5. Lothar Hennighausen

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil

    1. Francisco P. Freire-Neto
    2. Diego G. Teixeira
    3. Dayse C. S. da Cunha
    4. Ingryd C. Morais
    5. Celisa P. M. Tavares
    6. Genilson P. Gurgel
    7. Sanderson D. N. Medeiros
    8. David C. dos Santos
    9. Alexandre de O. Sales
    10. Selma M. B. Jeronimo

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. Second round of an interlaboratory comparison of SARS-CoV2 molecular detection assays used by 45 veterinary diagnostic laboratories in the United States

    1. Kaiping Deng
    2. Steffen Uhlig
    3. Laura B. Goodman
    4. Hon S. Ip
    5. Mary Lea Killian
    6. Sarah M. Nemser
    7. Jodie Ulaszek
    8. Shannon Kiener
    9. Matthew Kmet
    10. Kirstin Frost
    11. Karina Hettwer
    12. Bertrand Colson
    13. Kapil Nichani
    14. Anja Schlierf
    15. Andriy Tkachenko
    16. Mothomang Mlalazi-Oyinloye
    17. Andrew Scott
    18. Ravinder Reddy
    19. Gregory H. Tyson

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  10. Built environment’s impact on COVID-19 transmission and mental health revealed by COVID-19 Participant Experience data from the All of Us Research Program

    1. Wenting Luo
    2. Edwin Baldwin
    3. Anna Yi Jiang
    4. Shujuan Li
    5. Bo Yang
    6. Haiquan Li

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 173 of 716 Next